Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity

Abstract

The disclosure describes compositions containing conjugates using novel linkers, bivalent polysaccharide conjugates, and methods of bivalent polysaccharide conjugation in the development of multivalent conjugate vaccines. Conjugation of capsular polysaccharides to carrier proteins is carried out using homo-bifunctional and/or hetero-bifunctional linkers of specific lengths. Incorporation of the linkers and their use in bifunctional linkers induces higher titers of functional antibodies with high avidity, eliciting higher immunologic memory, and reduced carrier protein effect. This provides immunochemically cross-reactive capsular polysaccharides wherein one or more cross-reactive capsular polysaccharides are conjugated sequentially or concurrently to carrier protein using bifunctional linkers bearing the same or different functional groups. Such a linker and the size of the capsular polysaccharides provides an effective multivalent conjugate vaccine with high antibody titers and a reduced carrier effect and results in reduction in the content of the capsular polysaccharide and protein per dose of vaccine which reduces reactogenicity.

Description

BACKGROUND

1. Field of the Invention

The present invention is directed to multivalent conjugates, immunogenic compositions, and vaccines comprising carrier protein conjugated bacterial capsular polysaccharides and uses thereof. In particular, compositions of the invention comprise monovalent and multivalent bacterial capsular polysaccharide-protein conjugates, wherein the bacterial capsular polysaccharides and oligosaccharides are derived from serotypes of Streptococcus pneumoniae. The carrier protein is conjugated to bacterial capsular polysaccharides through mono functional as well as bi-functional linkers, preferably of defined lengths and the mono-functional or bi-functional linkers may be homo-mono-functional, homo-bi-functional, hetero-mono-functional, or hetero-bifunctional.

2. Description of the Background

Streptococcus pneumoniae is a Gram-positive pathogen responsible for invasive pneumococcal diseases (IPDs) such as pneumonia, bacteremia, meningitis, and acute Otitis media. Pneumonia is the most common manifestation of invasive pneumococcal disease, whereas bacterial spread within the respiratory tract may result in middle-ear infection, sinusitis or recurrent bronchitis. Pneumococcus is encapsulated with a chemically linked polysaccharide which results in serotype specificity. At least 90 pneumococcal serotypes are known of which about 23 account for 90% of invasive diseases and capsular polysaccharide is a poor immunogen.

There are currently three PCV vaccines available on the global market: PREVNAR®, SYNFLORIX®, and PREVNAR-13®. There is a need to address remaining unmet medical need for coverage of pneumococcal disease due to serotypes not found in PREVNAR-13® and potential for serotype replacement over time. There is a need for immunogenic compositions that can be used to induce an immune response against additional Streptococcus pneumoniae serotypes in humans and in children less than two years old.

A capsular polysaccharide (CPS) is a key virulence determinant and generally insufficiently immunogenic to induce a T cell-dependent immune response in infants and children. Conjugation of a carrier protein to CPS can induce an immune response that undergoes class switching. Accordingly, a 7-valent (PCV-7, Pfizer Inc., USA), a 10-valent (Synflorox-10, GSK Vaccines) and a 13-valent pneumococcal conjugate vaccine (PCV-13, Pfizer Inc., USA) have been developed to efficiently prevent the incidence of IPDs. Reductive amination chemistry and cyanylation chemistry has been widely used to prepare the conjugate vaccines.

In these conjugates, the short C—N linkage (2.1 Å) between CPS and carrier protein leads to steric shielding of the CPS epitopes by the carrier protein and low CPS/protein ratio. Important parameters are needed to minimize disadvantages of the current vaccines.

U.S. Pat. No. 9,492,559 discloses immunogenic compositions comprising conjugated capsular polysaccharide antigens and uses thereof. The immunogenic compositions disclosed include an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20-valent pneumococcal conjugate composition. Also disclosed is a 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 73, 24 or 25-valent pneumococcal conjugate composition.

International Application Publication No. WO 2014/097099A2 discloses a glycoconjugation process directed to several serotypes in addition to Preevnar-13 valent conjugates. New polysaccharide conjugates are added to formulation to increase efficacy of the vaccine.

U.S. Patent Application Publication No. 2011/023526 discloses a 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition. This patent is directed to 15-valent conjugate vaccines made by adding two or more serotypes with currently available 1-3 vaccines.

International Application Publication No. WO 2016/207905 discloses multivalent pneumococcal conjugate vaccine. This application is directed to a 13 or greater valent conjugate vaccine and deletion of serotype 6A.

U.S. Patent Application Publication No. 2017/007713 discloses a linker containing ((2-oxoethyl) thio) with enhanced functionality.

International Application Publication No. WO 2014/092377 discloses a 13 valent composition wherein 12 serotypes were selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and one from 12 or 9N.

International Application Publication No. WO 2014/092378 discloses an immunogenic composition having 13 different polysaccharide-protein conjugates wherein each conjugate contained a capsular polysaccharide isolated from 12 serotypes selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and serotypes 22F or 33F.

Chinese Application Publication No. 101590224 discloses a 14-valent pneumococcal polysaccharide-protein conjugate vaccine containing serotypes 1, 2, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F.

Chinese Application Publication No. 104069488 discloses 14 valent polysaccharide protein conjugate wherein the 14 serotypes were 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.

International Application Publication No. WO 2016207905 discloses a multivalent Pneumococcal conjugate vaccine comprising conjugates of CRM 197 and at least 14 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. U.S. Pat. No. 8,192,746 disclosed a 15 valent immunogenic composition comprising capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F conjugated to CRM197.

International Application Publication No. WO 2013/191459 discloses a 15 valent composition comprising S. pneumoniae capsular polysaccharides form serotypes of 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F and 23F.

Chinese Application Publication No. 103656632 discloses multi valent pneumococcal capsular polysaccharide composition containing serotype 6A and at least one extra serotype selected from the group consisting of 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F which provided protection against 24 different pneumococci serotypes.

Chinese Application Publication No. 103656631 discloses a multivalent pneumococcus capsular polysaccharide-protein conjugate composition comprising capsular polysaccharides of pneumococcus of 24 different serotypes viz. 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.

U.S. Patent Application Publication No. 2016/0324950 discloses immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, also referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX. This was meant for treatment of chronic diabetes mellitus, cancer, heart failure, neurologic, and urologic conditions. The carrier protein capsular polysaccharide conjugates varied.

U.S. Pat. No. 5,360,897 discloses immunogenic conjugate comprising reductive amination product of an intact capsular polymer of the bacterial pathogen S. pneumoniae having at least two carbonyl groups and a bacterial toxin or toxoid, said conjugate comprising a cross-linked conjugate in which there is a direct covalent linkage between the capsular polymer and the toxin or toxoid.

U.S. Pat. No. 7,862,823 describes a multivalent conjugate vaccine composition with at least two different carrier proteins.

U.S. Pat. No. 8,808,708 discloses a 13-valent immunogenic composition consisting of Polysaccharide-protein conjugates where serotypes consist of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, and wherein the carrier protein is CRMI97.

U.S. Patent Application Publication No. 2009/0017059 discloses an immunogenic composition where serotypes 19A and 19F were conjugated to different bacterial toxoids.

International Application Publication No, WO 2011/110241 describes pneumococcal conjugate immunogenic compositions or vaccines wherein different conjugation chemistries were used for different components of the immunogenic composition or vaccine. Reductive amination was used for the conjugation of at least one serotype and a conjugation other than reductive amination was used for the conjugation of a different serotypes. The conjugation method selected for different serotypes allowed each serotype to be presented using a conjugation method that allowed the best presentation of the saccharide epitope. Some pneumococcal saccharides conjugated well using reductive amination, whereas other pneumococcal saccharides were conjugated differently to allow the ring structure to remain unbroken and provide better results.

U.S. Pat. No. 7,955,605 discloses a process of making carrier protein polysaccharide conjugate consisting serotype 19A where the activated serotype 19A polysaccharide and carrier protein are resuspended in dimethyl sulfoxide (DMSO) to form a conjugate.

U.S. Patent Application Publication No. 2010/0074922 discloses immunogenic composition containing 10 or more serotypes wherein 19F capsular saccharide was conjugated to diphtheria toxoid (DT), serotype 18C capsular saccharide is conjugated to tetanus toxoid and serotypes 1, 4, 5, 6B, 7F, 9V, 14 and 23F capsular saccharides are conjugated to Protein D from Haemophilus influenza.

U.S. Patent Application Publication No. 2010/0239604 discloses a composition comprising multivalent S. pneumoniae capsular saccharide conjugates wherein serotype 19A was conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid and 2-9 of the S. pneumoniae capsular saccharides are conjugated to protein D. Apart from increasing the scope of protection by developing vaccines which will offer protection against larger number of serotypes, efforts were focused on developing newer methods of synthesis.

U.S. Pat. No. 7,709,001 describes a method of synthesis of carrier protein conjugate of capsular polysaccharide which consists of 1) reacting purified polysaccharide with a mild acid resulting in size reduction 2) reacting the polysaccharide of step 1 with an oxidizing agent in the presence of bivalent cations resulting in an activated polysaccharide; 3) compounding the activated polysaccharide with a carrier protein 4) reacting activated polysaccharide of step 3 and carrier protein with a reducing agent to form a polysaccharide—carrier protein conjugate; and 5) capping unreacted aldehydes in product of step 4 to yield an immunogenic polysaccharide-carrier protein conjugate.

International Application Publication No. WO 2014/097099 discloses a method of synthesizing a carrier protein conjugate, which involves a) reacting a saccharide with 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO) and N-chlorosuccinimide (NCS) in an aqueous solvent to produce an activated saccharide; and b) reacting the activated saccharide with a carrier protein comprising one or more amine groups.

U.S. Patent Application Publication No. 2012/321658 discloses an immunogenic composition wherein serotypes 1, 3, 19A and 19F linked to protein carriers either directly or indirectly through a chemistry other than reductive amination, and one or more different saccharides is/are selected from a second group consisting of serotypes 4, 5, 6A, 6B, 7F, 9V, 14, 18C and 23F which is/are linked to a protein carriers) by reductive amination.

Pneumococcal vaccines are based on 1) pneumococcal polysaccharide vaccine and 2) pneumococcal conjugate vaccines. PNEUMOVAX® marketed by Merck comprises of unconjugated polysaccharides belonging to serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18e, 19F, 19A, 20, 22F, 23F and 33F. Infants and young children respond poorly to most pneumococcal polysaccharides. Immunogenicity of poor immunogens is enhanced by conjugating with carrier proteins. Polysaccharide protein conjugate vaccines are made using capsular polysaccharides linked to protein carriers. The conjugate induces T cell dependent enhanced immune response against the specific serotype.

Conjugates are synthesized using various reagents, such as homo bifunctional, hetero bifunctional linkers of varying lengths. Three pneumococcal conjugate vaccines are available in market, PREVNAR®, SYNFLORIX®, and PREVNAR-13®. PREVNAR® is a heptavalent vaccine that contains the capsular polysaccharides from serotypes 4, 6B, 9Y, 14, 18C, 19F and 23F, each conjugated to a carrier protein designated CRM197. SYNFLORIX® is a deca-valent vaccine from GSK Biologicals that incorporates ten capsular polysaccharides conjugated to protein D from NTHi offering coverage against three additional pneumococcal strains, serotypes 1, 5 and 7F. PREVNAR-13® is a tri-deca-valent vaccine containing 13 capsular polysaccharide prepared from thirteen serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9Y, 14, 18C, 19 A, 19F, and 23F) conjugated to a carrier protein designated CRM197.

Increasing microbial resistance to antibiotics and the increasing number of immunocompromised persons have necessitated the development of pneumococcal vaccines with even broader protection, which leads to development of multivalent vaccines effective against increasing number of serotypes especially for coverage of pneumococcal disease due to serotypes not found in PREVNAR-13®. The need for a specific serotype depends on the region and antibiotic resistance developed. Thus, U.S. Pat. No. 8,192,746 reports a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9\1, 14, 18C, 19A, 19F, 22F, 23F, or 33F) conjugated to a carrier protein CRM197. There is a need for vaccines that induce an immune response against serotype 15B, 15C, and 15A.

With increasing number of polysaccharide antigens in the multivalent conjugate vaccine formulations, the carrier protein content increases. This increase leads to an increase of immune response to the carrier protein which can cause a systemic overload.

Thus, there is a need to develop a pneumococcal vaccine that provides protection against increasing number of serotypes. Although a higher valent vaccine is highly desirable with a conjugation, preferably the immune response to the carrier protein is also reduced. In the development of multivalent vaccines that extend the scope of protection to additional serotypes, there is a need to improve immunogenicity and avidity of the conjugate vaccine to accommodate the increased number of serotypes without compromising the immune responses to all, which is not possible with conventional conjugation methods. In addition to protection against increasing number of serotypes, there is also a need for to develop new linkers for conjugation to improve the immune response even with the increasing number of serotypes as well as a decrease in the carrier protein response (and also avoiding steric hindrance).

Although many references recite efficacy of currently available vaccines, when adding multiple new serotypes, the immune responses decrease with increase in numbers to the original serotypes. Additional serotypes are needed to increase the efficacy of the immune response. In addition, the greater efficacy should preferably include a reduction of the immune response to carrier protein. Thus, there remains a great need for higher valency pneumococcal conjugate vaccines to provide a barrier against infections throughout the world.

SUMMARY OF THE INVENTION

The present invention overcomes the problems and disadvantages associated with current strategies and designs and provides new immunogenic compositions comprising conjugated capsular saccharides and uses thereof.

One embodiment of the invention is directed to multivalent S. Pneumoniae conjugate vaccines comprising two groups of conjugates, wherein group one comprises monovalent bacterial capsular polysaccharide conjugates and group two comprises multivalent conjugates containing conjugates of bivalent bacterial capsular polysaccharide having cross reactivity. Preferably, group one conjugates are composed of monovalent capsular polysaccharide conjugates of one or more S. Pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B. Preferably, group two conjugates are composed of a bivalent or multivalent capsular polysaccharide conjugate of cross reactive serotypes of one, two or more of S. Pneumoniae serotypes 6A/6B/6C/6D, one, two or more of S. Pneumoniae serotypes 9V/9N/9A/9B, one, two or more of S. Pneumoniae serotypes 15B/15A/15C, or S. Pneumoniae serotypes 19A/19F; and carrier proteins. Preferably, the second group constituting the multivalent S. Pneumoniae conjugate vaccine comprises multivalent conjugates of S. Pneumoniae cross reactive serotypes wherein the conjugates are bivalent unimolecular and are derived from bacterial capsular polysaccharides. Preferably, the vaccine comprises capsular polysaccharide of two immunologically cross-reactive serotypes conjugated to the same carrier protein sequentially or concurrently. Preferably monovalent bacterial capsular polysaccharide conjugates of the first or second group are synthesized from native bacterial capsular polysaccharides with molecular weight ranges of 10 KDa to 50 KDa, 30 KDa-100 KDa, or 100 KDa-300 KDa.

Preferably, the bivalent capsular polysaccharide of two immunologically cross-reactive serotypes is represented by the formula PS1-Carrier Protein-PS2 and, also preferably, the conjugate comprises GAPS-CRM197-6BPS. Preferably the carrier protein comprises Tetanus Toxoid, Diphtheria Toxoid, CRM197, Tetanus Toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. Pertussis proteins, Pertussis toxoid (PT), Adenylate cyclase Toxin (ACT), 69 KDa protein, Human Papilloma viral protein antigens, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, or combinations thereof. Preferably a single dose of bivalent cross-reactive polysaccharide conjugates comprises less than 4 micrograms in comparison to monovalent conjugates of the same two polysaccharide vaccines which are 4 micrograms or more.

Preferably, total carrier protein quantity in the multivalent conjugate vaccine is significantly less than the quantity used in the mono conjugates of the individual polysaccharides of the same cross-reactive serotypes. Preferably, the vaccines of the present invention, the carrier protein amount being conjugated to a bivalent cross-reactive polysaccharide has less protein per serotype in comparison to that of the monovalent conjugates of the same two polysaccharides thereby the carrier protein immune response generated by the vaccine is lower than the response to the carrier protein of vaccines made by others containing the mono conjugates of the individual polysaccharides. Preferably total carrier protein content in the multivalent conjugate vaccine is from 0.5 to 0.7% by weight of the mono conjugates of the individual polysaccharides of the same cross-reactive serotypes (which is 1:1 ratio between PS: Carrier Protein). Preferably, the conjugate vaccine further comprises at least one adjuvant selected from the group consisting of aluminum or an aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, and/or a potent TLR7/8 agonist. Preferably the at least one adjuvant comprises an aluminum adjuvant selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide. Preferably the bacterial polysaccharides are selected from the group consisting of cross reacting two or more serotypes from different bacterial capsular polysaccharides and/or the bacterial polysaccharides comprise: S. pneumoniae and H. influenza type a, b serotypes; S. pneumoniae and Group B Streptococcus serotypes, H. influenza type a, b serotypes, or N. meningitis serotypes. Preferably the capsular polysaccharides comprise polysaccharides derived from Streptococcus pneumoniae, Haemophilus influenza, N. meningitis, Group B Streptococcus, or Moraxella catarrhalis lipo-oligosaccharides (LOS). Also preferably, the S. pneumoniae capsular polysaccharide is immunochemically cross-reactive with serotypes selected from the group consisting of 6A/6B/6C/6D; 9V/9A/9B, 9N; 15A/15B; 19A/19F and similar types of cross reactive polysaccharides. Preferably, the capsular polysaccharide is derived from Haemophilus influenza serotypes a/b/c/d/e/f, non-typeable Haemophilus influenza (NTHi) polysaccharides, or Moraxella catarrhalis Lipooligosaccharides (LOS), or N. meningitis serotypes A, B, C, Y, W-135 or X, or Group B Streptococcus serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII. IX and N, and N. meningitis serotypes A, C, Y, X, and W-135.

Another embodiment of the invention is directed to conjugate vaccines for the treatment or prevention of infection by Gram-positive and Gram-negative pathogens comprising a therapeutically effective amount of the conjugate vaccine of the invention and, optionally, a pharmacologically acceptable carrier. Preferably the capsular polysaccharides are derived from Haemophilus influenza, N. meningitis, Group B Streptococcus, N. meningitis, H. influenza, Moraxella catarrhalis lipo-oligosaccharides (LOS), and combination thereof.

Another embodiment of the invention is directed to methods for coupling polysaccharides with carrier protein comprising: activating the polysaccharide; attaching a define length spacer arm of about 2.0-40 Å to the activated polysaccharide; and attaching the activated polysaccharide attached spacer arm to a carrier protein.

Another embodiment of the invention is directed to methods coupling a carrier protein with polysaccharides comprising: activating the said carrier protein, reducing the carrier proteins disulfide to create sulfhydryl groups, preferably creating a sulfhydryl group using 2-iminothiolane (2-IT), SMPH like bi-functional linker; attaching a defined length spacer arm of 4-40 Å to the activated carrier protein; and attaching the polysaccharide to a spacer arm attached to activated carrier protein. Preferably the activated carrier protein is selected from the group consisting of cross-reactive material (CRM197) obtained or derived from C. diphtheria, or recombinant CRM197 obtained or derived from P. fluorescens or E. coli.

Another embodiment of the invention is directed to bifunctional linkers that are is homo-bifunctional or hetero-bifunctional.

Another embodiment of the invention is directed to multivalent S. Pneumoniae conjugate vaccine wherein carrier protein is cross-reactive material (CRM197) obtained from C. diphtheria, recombinant CRM197 obtained from P. fluorescens, or recombinant CRM197 obtained from E. coli.

Other embodiments and advantages of the invention are set forth in part in the description, which follows, and in part, may be obvious from this description, or may be learned from the practice of the invention.

DESCRIPTION OF THE FIGURES

FIG. 1A Size reduced capsular polysaccharide of serotype 6A 1H-NMR spectra (500 MHz)-NMR data shows no loss of structural integrity compared to native PS.

FIG. 1B Size reduced capsular polysaccharide of serotype 6B 1H-NMR spectra (500 MHz)-NMR data shows no loss of structural integrity compared to native PS.

FIG. 2A Capsular polysaccharide specific antibodies (total IgG) using multiplex bead based assay procedure (Polysaccharides used for these conjugates are in the range of 10-50 KDa).

FIG. 2B Capsular polysaccharide specific antibodies (total IgG) using multiplex bead based assay procedure wherein polysaccharides are in the range of 200-300 KDa or more.

FIG. 2C Bi-valent conjugates of 6A and 6B capsular polysaccharide specific antibodies (total IgG) using multiplex bead based assay procedure wherein polysaccharides are in the range of 10-50 KDa and 200-400 KDa.

FIG. 3A Monovalent conjugates synthesis work flow chart.

FIG. 3B Flow chart of PS1 and PS2 activation with linkers.

FIG. 4A Bivalent unimolecular conjugates and bi-valent conjugates synthesis workflow chart.

FIG. 4B CRM chemical couplings.

FIG. 5 CDAP (1-cyano-4-dimethylaminopyridinium tetrafluoroborate, Cyanuric chloride (2,4,6-Trichloro-1,3,5-triazine), cyanogen bromide (CNBr).

FIG. 6 Thiolation of CRM 197 with iminotiolene.

DESCRIPTION OF THE INVENTION

Streptococcus pneumoniae is a Gram-positive bacterium which can cause diseases such as pneumonia, bacteraemia, meningitis, and acute Otitis media. Pneumococcus is encapsulated with a chemically linked polysaccharide which results in serotype specificity. At least 90 pneumococcal serotypes are known of which about 23 account for 90% of invasive diseases. The protection against invasive pneumococci disease is related to the antibody specific to the capsular polysaccharide, the protection is therefore serotype specific.

It was surprisingly discovered that multivalent S. Pneumoniae conjugate vaccine comprising of a linker between the carrier protein and the polysaccharide to form two groups of conjugates, wherein group one comprises monovalent bacterial capsular polysaccharide conjugates and the other group comprises multivalent carrier protein conjugates provides substantially improved results. Specifically, the bivalent conjugates and bivalent unimolecular conjugates are preferably synthesized by the reaction between carrier protein and bifunctional linkers attached to cross reactive S. Pneumoniae serotypes. Results achieved are substantially improved compared to vaccines containing multivalent S. Pneumoniae conjugate vaccine containing monovalent bacterial capsular polysaccharide conjugates with the same number of serotypes with a direct conjugation between the two instead of a linker.

One embodiment of the invention is directed to multivalent conjugate vaccines comprised of bivalent-polysaccharide protein conjugates with enhanced immunogenicity. Bivalent conjugates with general structure PS1-carrier protein-PS2 have higher immunogenicity compared to similar monovalent conjugates wherein PS1 and PS2 are two different serotype polysaccharides from gram-negative and gram-positive bacterial pathogens. By developing a bi-valent conjugate vaccine, the efficacy of the vaccine increases and carrier immunogenicity is reduced. The chemistry disclosed herein substantially increases the conjugates immunogenicity, at the same time reduces carrier protein load.

Another embodiment of the invention is directed to vaccines with lower molecular weight polysaccharides and longer arm bifunctional linkers preferably with enhanced immunogenicity. Another embodiment of the invention is directed to providing higher immunogenicity and avidity of bivalent conjugates as well as lower carrier protein immunogenicity. Another embodiment of the invention is directed to reducing conjugate vaccine dose with higher immunogenicity.

As disclosed herein, four parameters have been introduced to minimize the disadvantages of conventional vaccines:

• • Polysaccharide size is preferably 10-50 KDa.
  • Cross-reactive polysaccharides concurrent conjugation to carrier protein.
  • Two or more cross reactive serotypes are conjugated concurrently with carrier proteins.
  • A long hetero- or homo-bifunctional spacer arm preferably of from 2-40 Å (also 2-40 Å, 4-40 Å, 10-40 Å, 20-40 Å, 9-20 Å, 5-20 Å, 5-30 Å).

These four parameters taken together are profoundly effective to increase the conjugates polysaccharide/protein ratio, to reduce carrier protein load, and to provide several folds of increase in immunogenicity and avidity.

The present invention is directed to polysaccharide-protein conjugates with enhanced immunogenicity displaying significantly high antibody titers. The carrier protein is obtained from, for example, tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, B. Pertussis proteins like pertussis toxoid (PT), adenylate cyclase toxin (ACT), 69 KDa protein and Human Papilloma viral protein antigens or its VLP form, Hepatitis B core antigen or its VLP form or derivatives of HBsAg, and other conventional carriers. Polysaccharide fragment is obtained from group of group of gram positive bacteria and gram-negative bacteria, preferably from immunochemically cross-reactive polysaccharides of S. Pneumoniae. The present invention is also directed to a process of preparing the polysaccharide-protein conjugates in which carrier protein reacts with cleaved and depolymerized polysaccharide fragments of optimum chain length.

Immunogenic compositions of the present invention provide for appropriate level and improved protection against S. pneumoniae serotypes not found in PREVNAR-13 ®, and SYNFLORIX-10®.

Bivalent conjugates with cross-reactive polysaccharides of S. Pneumoniae serotypes (6A/6B, 9V/9N, 15A/15B and 19A/19F and similar cross-reactive serotypes) with short chain molecular size (10-50 KDa) was used to prepare 16-26-valent pneumococcal CPS conjugate vaccine in the present study. Pneumococcus type 6A and 6B polysaccharide was used as the model cross-reactive CPSs. CRM197 was used as the carrier protein for its clinical acceptance.

Multivalent monoconjugates have also been prepared using shorter PS chain length (0-50 KDa), long spacer arm (9-40 Å) with homo or hetero-bifunctional PEG or non-PEG linker with carrier protein CRM197.

CPS was activated either by oxidation or by cyanylation chemistry and oxidized by sodium periodate and introduced with either-reactive aldehyde or isothiocyanate (—OCN) groups in CPS.

Two strategies (short and long linker, short and long CPSs) were used to introduce, respectively. Physicochemical and immunological characteristics of the bivalent conjugates vaccines were then investigated independently or combining with multivalent conjugate formulation.

The following examples illustrate embodiments of the invention, but should not be viewed as limiting the scope of the invention.

EXAMPLES

Example 1 Polysaccharide Size Reduction, Activation and Conjugation Process for Multiple S. pneumoniae Serotypes-1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 10A, 11A, 12F, 14, 15A, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F and 35B

6A and 6B Polysaccharide

100 mg each of capsular polysaccharides of S. pneumoniae 6A and 6B is dissolved in 10 ml of aqueous solution containing 10 mM of Acetic acid or 0.1 M HCl at pH 2.5-3.0 and hydrolysis is carried out by maintaining the solution at a temperature of 60-85° C. for a period of 60-120 mins. The so-obtained oligosaccharides after neutralization, diafiltered using 3-10 KDa TFF Centricon filters. Upon ¹H NMR analysis (FIGS. 1A and 1B), the oligosaccharides formed show no loss of structural integrity or loss of epitope or repeat unit structure. Polysaccharides were measured using Anthrone assay and molecular size distributions (KDa) obtained are in the range of 10-50 KDa, 30-100 KDa, and 100-300 KDa.

CPS (50 mg) moiety (native polysaccharides of size between ≥200-500 KDa or size-reduced polysaccharides of size between 10-50 KDa) were activated cyanylation reagents commonly used in activation process (Table 1). Polysaccharide molecular size distributions were determined using SEC-HPLC (Shodex SB-405 and SB-406 SEC columns) with analysis using (10-1000 KDa) Pollulan mixture as reference standard (Pollulan standards from Shodex, USA).

Short spacer arm was introduced to PS by reaction with 5-8-fold molar excess of ADH (Sigma) at pH 5.6-6.0 for 3-5 hr. Long spacer arm (bifunctional linker or long 4-arm linker) was introduced into PS by reaction with 5-10-fold molar excess of at pH 5.6-6.0 for 3-5 h.

TABLE 1
Polysaccharide size distribution (KDa) used for conjugation
	PS	Polysaccharide KDa
	6A	10-30	KDa
	6B	20-50	KDa
	15B	20-40	KDa
	18C	20-50	KDa
	22F	10-30	KDa

Activated PS is further derivatized with short arm linker (adipic acid di-hydrazide, ADH, 174.2 g/mole), one more spacer arm linkers with varying size from 2-4 Å to 8-20 Å (600 g/mol-3.5 g/mole).

Homo or hetero-bifunctional PEG linkers with diamine functional groups attached, e.g. NH2-PEG0.6K—NH2, NH2-PEG3.5K—COOH (Table 2).

TABLE 2
Short and long chain linker used for polysaccharide or carrier protein derivatization
used (several other linkers either in pegylated form or non-pegylated form have also
been used)
Linker No.	Linker Structure	Chemical Structures/KDa or Å used
1	NH2—PEG—NH2/NHS	H2N—(CH2CH2O)n—CH2CH2—NH2
		1K and 3.5K
2	NHS/NH2—PEG—COOH
3	Mal-PEG—NH2
4	Mal-PEG—NHS
5	CHO—PEG—CHO
6	SH—PEG—NH2	HS—(CH2CH2O)n—CH2CH2—NH2
		1K and 3.5K
7	ADH
8	HZ-PEG-HZ
9	SMPH
11	SMCC
12	4-Arm-PEG—NH2 or NHS
Mal-Maleimide, NHS-Succinimide, PEG-Polyethylene glycol derivatives, ADH-Adipic acid di-hydrazide.

Two aliquots of 2 ml each of the derivatized CPS (10 mg/ml) were mixed with 1 ml aliquot of the two CRM197 protein samples (10 mg/ml) at 4° C. for 8-12 hrs. The conjugates with long and short spacer arm were purified by a 100-300 KDa Centricon filters (EMD Millipore) (Table 3).

TABLE 3
Physicochemical Characterization of mono-valent Conjugates
	Activated PS KDa	Conjugate KDa	PS:Protein	Free
PS	by SEC-HPLC	by SEC-HPLC	ratio	PS %
6A	10-30 KDa, 200-300 KDa	>200-300, >2500	0.5-2, 1-2	<2
6B	20-50 KDa, 200-400 KDa	>300-500, >2500	0.5-2, 1-2	<1
15B	20-40 KDa	>300-500	0.5-2, 1:1	<1
18C	20-50 KDa	>300-500	0.5-2, 1:1	<2
22F	10-30 KDa	>200-300	0.5-2, 1:1	<1
Note:
Internal std. for KDa determination of PS for SEC-HPLC:Pullulan std. mixture (2 KDa-2500 KDa).

Example 2 Activation of Size Reduced Polysaccharides of Different Molecular Weights Oligosaccharides of Different Molecular Weights Synthesized as Described in Example 1 were Activated. Cyanylation Reagents Commonly Used in Activation Process

CDAP (1-Cyano-4-dimethylaminopyridinium tetrafluoroborate (Sigma Aldrich, USA)) cyanuric chloride (2,4,6-trichloro-1,3,5-triazine) or cyanogen bromide (CNBr) and coupling carrier protein (see FIGS. 5 and 6).

Polysaccharide solution (10 mg/ml) was incubated with 10 mg/ml CDAP (100 mg/ml in acetonitrile) in 2M NaCl or 200-300 mM bicarbonate buffer at RT for 4-6 minutes. pH was maintained at 10-10.5 using either 1N NaOH or 1N HCl. Then, pH was adjusted to 8.1-8.2, pegylated linkers (Hz-PEG-HZ) were allowed to react with CDAP treated PS. For 8-12 hrs at RT. The reaction mixtures were depth filtered followed by 100-300 KDa cutoff centricon fiters 5-8 times using 150 mM NaCl.

Derivatization of Activated Size Reduced Polysaccharides

Activated oligosaccharides were further derivatized with short chain homo-bifunctional hydrazide linker. Typical reagent was adipic Acid di-hydrazide, ADH, Molecular weight 174.2 g/mole). Homo or hetero-bifunctional PEG linkers bearing di-amine, di-hydrazide, or amine or hydrazide-carboxylic acid/aldehyde functional groups, e.g. NH2-PEG(1K-3.5K)—NH2, HZ-PEG(1-3.5K)—HZ, NH2-PEG3.5K—COOH were used. (Table 2). Several other homo- or hetero-bifunctional spacer arms can also be used for derivatization (Table 2). Short spacer arm was introduced to oligosaccharide by reaction with 5-8 fold molar excess of adipic acid di-hydrazide (Sigma) at pH 5.8-6.0 for 3-5 hr. long chain linker (bifunctional linker or long tetra functional linker (Table 2), No. 12 four arm linker) was introduced into Polysaccharide by reaction with 5-10-fold molar excess of the linker to the oligosaccharide at pH 5.8-6.0 for 3-5 hrs. at RT.

Derivatization of Carrier Protein with Short or Long-Linkers

Carrier protein CRM197 was further derivatized with short chain homo-bifunctional hydrazide linker. Typical reagent was adipic Acid di-hydrazide, ADH, molecular weight 174.2 g/mole). Homo or hetero-bifunctional PEG linkers bearing di-amine, di-hydrazide, or amine or hydrazide-carboxylic acid/aldehyde functional groups, e.g., NH2-PEG(1K-3.5K)—NH2, HZ-PEG(1-3.5K)—HZ, NH2-PEG3.5K—COOH were used. (Table 2). Several other homo- or hetero-bifunctional spacer arms can also be used for derivatization as listed in Table 2). Short spacer arm was introduced to carrier protein CRM197 by reaction with 5-8 fold molar excess of adipic Acid di-hydrazide (Sigma) at pH 5.8-6.2 in 300-600 mM MES buffer for 3-5 hr at RT. Long chain linker (bifunctional linker or long tetra functional linker (Table 2, No. 12 four arm linker) was introduced into carrier protein by reaction with 5-10-fold molar excess of the linker to the oligosaccharide at pH 5.8-6.2 in 300-600 mM MES buffer for 3-5 hr at RT (room temperature).

Example 3 Cross-Reactive Polysaccharide Serotypes Activation and Attachment of Short or Long-Spacer Arm Linkers (Serotypes of Interest are 6A/6B, 9V/9N, 15A/15B and 19A/19F or any Other Cross-Reactive Serotypes)

Activation of the oligosaccharide derived from the capsular polysaccharide of S. Pneumoniae Type 6A and 6B conjugation with CRM197 and introduction of the primary amino groups to the oligosaccharides concurrently.

Native or size reduced polysaccharide of serotype 6A and 6B (≥200-400 KDa) were conjugated using the same procedure as described in Examples 1 and 2.

The oligosaccharides mixture thus obtained as reported in Example 1 are dissolved in WFI, to an end concentration of 10 mg/ml. At the end of the reaction, the Oligosaccharide are purified by diafiltration using 3-10 KDa Centricon filters.

The Oligosaccharides into which the amino groups have been introduced are diluted to a concentration of 10 mg/ml in an aqueous solution of DMSO (at 20-30% v/v) to DMSO containing ADH short linker or long spacer arm linkers in molar excess relatively to the amino groups introduced into the oligosaccharide (usually 5-10:1). The reaction was carried out by keeping the solutions at RT for a time of 4-12 hours. At the end of the period, oligosaccharide was again purified using 3-10 KDa Centricon filters.

Example 4 Synthesis of Pneumococcal Polysaccharide Monovalent Conjugates

Two separate aliquots of same or differently size reduced and derivatized size reduced Polysaccharides (with short spacer arm ADH and Long spacer arm HZ-PEG-HZ) as synthesized in example 3 (10 mg/ml) were mixed with 1 ml aliquot of the CRM197 protein sample (10 mg/ml) at 4° C. for 8-12 hrs. The conjugates containing both long and short chain linkers were purified using 100-300 KDa centricon filters (EMD Millipore). Each monovalent conjugates were assayed for total polysaccharide content by either anthrone or uronic acid assay, total protein content by BCA or Lowry assay (Table 4).

All other cross-reactive Polysaccharide conjugates are made using the same procedure as above.

TABLE 4
Physicochemical Characterization of Bi-valent
Conjugate of general structure 6A-CRM197-6B
			Oligosac-	Free
	Activated		charide:Protein	Oligosac-
	Oligosac-		ratio	charide %
PS	charide KDa	Conjugate KDa	(Weight ratio)	by weight
6A	≥100-300 KDa	>200-300 KDa,	0.5-2, 1-2	<2
		>2500 KDa
6B	≥200-400 KDa	>300-500 KDa,	0.5-2, 1-2	<1
		>2500 KDa
6C	≥200-400 KDa	>300-500 KDa,	0.5-2, 1-2	<1
		>2500 KDa
15B	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<1
		>1500 KDa
15A	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<1
		>1500 KDa
18C	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<2
		>1500 KDa
22F	≥100-300 KDa	>200-300 KDa,	0.5-2, 1:1	<1
		>1000 KDa
1	≥100-300 KDa	>200-300 KDa,	0.5-2, 1-2	<2
		>2500 KDa
3	≥200-400 KDa	>300-500 KDa,	0.5-2, 1-2	<1
		>2500 KDa
4	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<1
		>1500 KDa
7F	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<2
		>1500 KDa
9V	≥100-300 KDa	>200-300 KDa,	0.5-2, 1:1	<1
		>1000 KDa
9N	≥100-300 KDa	>200-300 KDa,	0.5-2, 1:1	<1
		>1000 KDa
14	≥100-300 KDa	>200-300 KDa,	0.5-2, 1-2	<2
		>2500 KDa
18C	≥200-400 KDa	>800 KDa,	0.5-2, 1-2	<1
		>2500 KDa
19A	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<1
		>1500 KDa
19F	≥100-300 KDa	>300-500 KDa,	0.5-2, 1:1	<2
		>1500 KDa
23F	≥100-300 KDa	>200-300 KDa,	0.5-2, 1:1	<1
		>1000 KDa
33F	≥100-300 KDa	>200-300 KDa,	0.5-2, 1-2	<2
		>2500 KDa
Note:
Internal std. for SEC-HPLC (KDa):Pollulan std mixture (2 KDa-1200 KDa)

Example 4 Investigational Formulation of 16V- or Higher Valent Pneumococcal Conjugate Vaccine

Pneumo Polysaccharide-CRM197 conjugates for serotypes containing 1, 3, 5, 7F, 14, 15B, 18C, 22F, 23F, 33F, 35B and cross-reactive polysaccharide conjugates 6A, 6B, 9V, 9N, 15A, 15B, 19A, and 19F were combined to yield final antigen concentration of 4.0 μg PS/mL. Sodium chloride (150 mM) solution, 10-20 mM Histidine, Succinic acid and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant. 16-V conjugate was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) or PREVNAR-13® (Pfizer, USA) was used as two control commercial vaccine formulation.

Example 5 Immunogenicity Studies of Conjugates

A New Zealand white rabbit model (NZW) was selected in this work to compare the immunogenicity of the Pneumo PS-CRM197 conjugates. Rabbits from all groups (16-V {valent}, PREVNAR-13®, and PNEUMOVAX®) were examined for clinical signs before and after immunization periods. For all groups, pre-immunization, booster dose (7 and 14-days) and terminal bleed (28 days) were collected and aliquoted and store at minus 80° C. until use. Multiplexed Immunogenicity assay for the determination of Total IgG were performed according to the standard protocol using reference standard serum 007 (CBER, FDA, USA). Reference serum and rabbit serum were diluted and pre-adsorbed for cross-reacting antibodies by treatment with pneumococcal CWPS and either 22F PS or 25 PS. Human monoclonal anti-polysaccharide antibodies (Pamlico Biopharma, USA) were used for total IgG estimation. Bio-Plex 200 (Bio-Rad). Multiplex reader was used as per manufacturer's instructions (see FIGS. 2A, 2B and 2C).

Example 5 S. Pneumoniae Cross-Reactive Capsular Polysaccharide Serotypes Activation and Attachment of Short and Long-Spacer Linkers

Serotypes of 6A/6B, 9V/9N, 15A/15B and 19A/19F which are cross-reactive serotypes are used for the synthesis of bi-valent conjugates containing capsular poly saccharides and carrier protein. Bivalent conjugates by definition contain two capsular polysaccharide attached to CRM 197 simultaneously or concurrently.

Activation of the size reduced polysaccharide derived from the capsular polysaccharide of S. Pneumoniae Type 6A and 6B, conjugation with CRM197 and introduction of the primary amino or hydrazide groups to the oligosaccharides carried out concurrently.

Native polysaccharides or size reduced oligosaccharide of serotype 6A and 6B (≥200-500 KDa) were conjugated using the same procedure as described in Example 1-4.

The size reduced polysaccharides mixtures thus obtained were dissolved in water for injection, so that the final concentration was 10 mg/ml. The size reduced polysaccharides into which the amino or hydrazide groups were introduced were diluted to a concentration of 10 mg/ml in an aqueous solution of dimethyl sulfoxide (DMSO) so the percentage of DMSO was in the range of 20-30% (v/v). This was added to DMSO containing short chain linker such as ADH or long chain linkers as described in Table 2 in molar excess relatively to the amino/hydrazide groups introduced into the size reduced polysaccharides (usually 5:1 or 10:1), more specifically 8:1.

The reaction was carried out at room temperature for a duration of 4-12 hours. At the end of the reaction period, the reaction product was again purified using 3-10 KDa Centricon filters.

Example 6 Simultaneous or Concurrent Conjugation of S. pneumoniae Oligosaccharides of Type 6A and Type 6B with CRM197 Carrier Protein as Bivalent Conjugates Manufacturing

The aqueous solution containing 15 mg/ml of CRM197, was added to DMSO containing the linker attached oligosaccharide (20-30% in water) derived from the capsular polysaccharide of S. pneumoniae Type 6A. The ratio of linker attached oligosaccharide to CRM197 was selected from 1:1, 2:1, 1:2. The mixture so obtained was kept, under mild stirring, at room temperature for 8-12 hrs. At the end of said time, the solution containing the derivatized oligosaccharide derived from the capsular polysaccharide of S. Pneumoniae 6B was added. The molar ratio of capsular polysaccharide of S. Pneumoniae 6B to the CRM197, was selected from 1:1, 2:1, 1:2). The resulting mixture was kept for 8-12 hrs at room temperature (Table 5). The conjugation reaction can also be carried out by adding, at the same time (concurrently), to the CRM197-containing solution, the two-activated oligosaccharide respectively derived from the capsular polysaccharide of S. pneumoniae Type 6A and from the capsular polysaccharide of S. pneumoniae Type 6B. The oligosaccharide-protein conjugates so obtained were dialyzed using 100-300 KDa dialysis membrane (Spectrum lab, USA), conditioned in 0.01 M phosphate buffer containing 0.2M NaCl (pH=6.6-7.0) and finally filtered through a 0.22 μm filter.

All other cross-reactive Polysaccharide conjugates were made using the same procedure as used above. Reaction sequences are depicted in FIGS. 3A, 3B, 4A, and 4B.

TABLE 5
Comparisons of PS Contents
	Activated		Total Poly-	Free
Bivalent	oligosac-		saccharide	oligosac-
Oligosac-	charide		Protein ratio	charide %
charide	KDa	Conjugate KDa	by weight	by weight
6A-6B	≥100-300	2.0:1.5	2-1.5	(1:0.75)	<2
6A-6B	≥100-300,	>1200-2500 KDa	2-1.4	(1:0.7)	<3
	≥300
19A-19F	≥100-300	>500-800 KDa	2-1.6	(1:0.8)	<2
15A-15B	≥100-300,	>500-1000 KDa	2-1.3	(1:0.65)	<3
	≥300
9V-9N	≥100-300,	>500-1000 KDa	2-1.3	(1:0.65)	<3
	≥300

Example 7 Investigational Formulation of 18-Valent or Higher Valent Pneumococcal Conjugate Vaccine

Pneumococcal Polysaccharide-CRM197 conjugates for serotypes containing 1, 3, 5, 7F, 14, 18C, 22F, 23F, 33F, 35B (10 serotypes Polysaccharides) and cross-reactive polysaccharide conjugates of (6A, 6B), (9V, 9N), (15A, 15B) and (19A, 19F) (8 serotypes) were combined to yield final polysaccharide concentration of 2.2-4.4 μg PS/mL (1.1-2.2 μg/human dose, 0.5 mL). Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant.

18-valent or higher valent (>20V-24V) conjugate was aseptically filled in 2 mL sterile vials. PNEUMOVAX® (Merck, USA) and/or PREVNAR-13® (Pfizer, USA) were used as controls.

Example 9 Immunogenicity Studies of the Conjugates

A New Zealand white rabbit model (NZW) was selected in this work to compare the immunogenicity of the Pneumococcal PS-CRM197 conjugates. Rabbits from all groups (18 or higher-Valent conjugates, PREVNAR-13®, Pfizer and PNEUMOVAX®-23 (Merck USA) were examined for serological titers before and after immunization periods. For all groups, pre-immunization, booster dose (7 and 14-days) and terminal bleed (28 days) were collected and aliquoted and store at −80° C. until use. Immunogenicity assay for the determination of Total IgG were performed according to the standard protocol using reference standard serum 007 (CBER, FDA, USA). Reference serum and Rabbit serum were diluted and pre-adsorbed for cross-reacting antibodies by treatment with Pneumococcal CWPS and non-vaccine serotype 25 PS. Human/rabbit/mouse monoclonal anti-polysaccharide antibodies were used for total IgG estimation. Bio-Plex 200 (Bio-Rad) reader were used as per the manufacturer's instructions.

Immunogenicity of the conjugates, i.e. capsular polysaccharide specific antibodies (total IgG) were measured using bead-based ELISA assay method were given in Table 6. Total IgG values were compared head to head with PREVNAR-13® in rabbit immunogenicity data. 14-day data shows significant increase in titer in IVT-18V-1 vaccine compared to PREVNAR-13® vaccine. Similarly, IVT-18V-1 data has significant booster on IgG values as compared to PREVNAR-13® (Table 6).

TABLE 6
Capsular Polysaccharides specific antibodies (Total
IgG in μg/ml) using Multiplex bead-based ELISA
assay for 18V-monovalent conjugate vaccines
PREVNAR-	(IgG) 14	(IgG) 28	IVT-18V-	(IgG) 14	(IgG) 28
13 ® 2.2	day/zero	day/Zero	1 2.2	day/Zero	day/Zero
μg/dose	day	day	μg/dose	day	day
1	45	350	1	375	1500
3	47	200	3	48	480
6A	188	560	6A	775	3775
6B	165	780	6B	662	3662
18C	50	280	18C	306	3560
19A	45	235	19A	233	2500
19F	29	290	19F	72	720
4	49	230	4	150	750
5	186	700	5	550	3550
7F	180	680	7F	332	3860
9V	52	520	9V	212	2400
9N	—	—	9N	200	2200
14	85	400	14	272	2890
15A	—	—	15A	672	3900
15B	—	—	15B	750	4000
18C	175	800	18C	550	5500
22F	—	—	22F	1000	8000
23F	53	450	23F	212	2420
Note:
IVT-18V == 18-V conjugate vaccine (monovalent conjugates mixed together); 9N, 15A, 15B, 22F and 23F serotype are not present in PREVNAR-13 ®, so IgG values not measured; 18-V formulation as monovalent conjugates were prepared using 2.2 μg for each serotype except 4.4 μg of 6B conjugate. Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant; capsular polysaccharides antibodies (total IgG) using bead-based ELISA: 18-V conjugate vaccine formulation-2 (IVT-18V-2): 10-V formulation as monovalent conjugates and remaining 8-V added as bivalent-conjugates which includes 6A/6B, 9V/9N, 15A/15B and 19A/19F. (vaccine dose used as 2.2 μg for each serotype except 4.4 μg of 6B) 10-V formulation as monovalent conjugates and remaining 8-V added as bivalent-conjugates which includes 6A/6B, 9V/9N, 15A/15B and 19A/19F. 6A-6B bivalent unimolecular conjugates are used as 2.2 μg/dose, remaining bivalent conjugates are used as 2.2 μg/dose. Sodium chloride (150 mM) solution, 10-20 mM histidine, 20 mM HEPES or MOPS buffer and 0.001% Tween-20 was also used during the formulation process as diluent, and aluminum phosphate (Adju-Phos, Brenntag, USA) was used as investigational adjuvant.

Immunogenicity of the conjugates, capsular polysaccharide specific antibodies (total IgG) were measured using bead-based ELISA assay method were given in Table 7. Total IgG values were compared head to head with PREVNAR-13® in rabbit immunogenicity data. 14-day data shows significant increase in titer in IVT-18V-2 vaccine compared to PREVNAR-13® vaccine. Interestingly, IVT-18V-2 total IgG data for bivalent conjugates serotypes (for example. 6A/6B, 9V/9N, 15A/15B, and 19A/19F) has significant booster on IgG values as compared to IVT-18V-1 formulation with monovalent conjugates. Therefore, it can be concluded that Bivalent conjugates has better immunogenicity in comparison to monovalent conjugates (Table 7). Therefore, IVT-18V-2 conjugate vaccine formulation has superior immunogenicity not only against PREVNAR-13® but also against IVT-18V-1 formulation. Polysaccharide conjugated with either 1-3.5K linker (HZ-PEG-HZ) elicits much higher immunogenicity in compared to short linker (ADH) or no linker conjugates as in PREVNAR-13®.

TABLE 7
Capsular Polysaccharides antibodies (total
IgG) using Multiplex bead-based ELISA
PREVNAR-			IVT-18V-
13 ® 2.2	Ratio 14	Ratio 28	2 2.2	Ratio 14	Ratio 28
μg/dose	day/0 day	day/0 day	μg/dose	day/0 day	day/0 day
1	45	350	1	375	1500
3	47	200	3	50	530
6A	188	560	6A/6B	875/762	4375/4662
6B	165	780
18C	50	280	18C	316	3600
19A	45	235	19A/19F	300/198	3500/2700
19F	29	290
4	49	230	4	180	1000
5	186	700	5	550	3600
7F	180	680	7F	360	4100
9V	52	520	9V/9N	350/300	3400/3200
9N	—	—
14	85	400	14	310	32000
15A	—	—	15A/15B	872/850	5900/5600
15B	—	—
18C	175	800	18C	600	6800
22F	—	—	22F	1020	8150
23F	53	450	23F	300	3200
Note:
1VI-18V-2 = 10-monovalent conjugates and 4 bivalent conjugates mixed together; 18-V conjugate vaccine formulation (IVT-18V-3): 10-V formulation as monovalent conjugates used as 2.2 μg/dose and remaining 8-V added as bivalent-conjugates which includes 6A/6B, 9V/9N, 15A/15B and 19A/19F used as 1.1 μg/dose, except 6B 2.2 μg/dose.

Immunogenicity of the conjugates, i.e. capsular polysaccharide specific antibodies (total IgG) were measured using Multiplex bead-based ELISA assay method were given in Table 8. Total IgG values were compared head to head with PREVNAR-13® in rabbit immunogenicity data. 14-day data shows significant increase in titer in IVT-18V-3 vaccine compared to PREVNAR-13® vaccine. Interestingly, IVT-18V-3 formulations with lower dose (2.2 vs 1.1 ug dose), total IgG data for bivalent conjugates serotypes (for example. 6A/6B, 9V/9N, 15A/15B, and 19A/19F) has comparable IgG values as compared to IVT-18V-2 formulations for bivalent conjugate serotypes. Therefore, it can be concluded that bivalent conjugates has better immunogenicity in comparison to monovalent conjugates with lower dose. Therefore, IVT-18V-2 conjugate vaccine formulation has superior immunogenicity not only against PREVNAR-13® but also against IVT-18V-1 formulation. Polysaccharide conjugated with either 1-3.5K linker (HZ-PEG-HZ) elicits much higher immunogenicity in compared to short linker (ADH) or no linker conjugates as in PREVNAR-13® (Table 8).

TABLE 8
Total IgG data for bivalent conjugates serotypes
PREVNAR-			IVT-18V-
13 ® 2.2	Ratio 14	Ratio 28	2 2.2	Ratio 14	Ratio 28
μg/dose	day/0 day	day/0 day	μg/dose	day/0	day/0 day
1	45	350	1	375	1500
3	47	200	3	50	530
6A	188	560	6A/6B	825/860	4275/4900
6B	165	780
18C	50	280	18C	316	3600
19A	45	235	19A/19F	275/250	3400/3000
19F	29	290
4	49	230	4	180	1000
5	186	700	5	550	3600
7F	180	680	7F	360	4100
9V	52	520	9V/9N	320/380	3300/3800
9N	—	—
14	85	400	14	310	32000
15A	—	—	15A/15B	790/900	5800/6200
15B	—	—
18C	175	800	18C	600	6800
22F	—	—	22F	1020	8150
23F	53	450	23F	300	3200
Note:
1VI-18V-3 = 10-monovalent conjugates and 4 bivalent conjugates mixed together.

Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. All references cited herein, including all publications, U.S. and foreign patents and patent applications, are specifically and entirely incorporated by reference. It is intended that the specification and examples be considered exemplary only with the true scope and spirit of the invention indicated by the following claims. Furthermore, the term “comprising of” includes the terms “consisting of” and “consisting essentially of.”

Claims

1. An immunogenic composition comprising: first and second group conjugates, wherein: first group conjugates comprise a first collection of monovalent conjugates, wherein each monovalent conjugate comprises a first carrier protein and a capsular polysaccharide of Streptococcus pneumoniae and the first collection includes capsular polysaccharides of Streptococcus pneumoniae serotypes 1, 2, 3, 4, 5, 7F, 8, 10A, 11A, 12F, 14, 17F, 18C, 20, 22F, 23F, 24F, 33F and 35B; andsecond group conjugates comprise a second collection of bivalent and/or multivalent conjugates, wherein each bivalent or multivalent conjugate comprises a second carrier protein and at least two capsular polysaccharides of Streptococcus pneumoniae, selected from one or more of the groups consisting Streptococcus pneumoniae serotypes 6A, 6B, 6C, and and/or 6D, Streptococcus pneumoniae serotypes 9V, 9N, 9A and 9B, Streptococcus pneumoniae serotypes 15B, 15A, and 15C, and Streptococcus pneumoniae serotypes 19A and 19F, wherein one or more of the capsular polysaccharides are coupled via a bifunctional linker, wherein the multivalent conjugate contains a quantity of carrier protein that is less than a quantity of capsular polysaccharide.

2. The immunogenic composition of claim 1, wherein the second group conjugates are bivalent conjugates.

3. The immunogenic composition of claim 2, wherein the bivalent conjugates comprises two immunologically cross-reactive serotypes represented by the formula PS1-Carrier Protein-PS2, wherein PS1 and PS2 represent different polysaccharides and carrier protein refers to the second carrier protein.

4. The immunogenic composition of claim 2, wherein the bivalent conjugates are conjugated to the same carrier protein sequentially or concurrently.

5. The immunogenic composition of claim 1, wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 10 kDa to 50 kDa.

6. The immunogenic composition of claim 1, wherein the bifunctional linker further comprises a spacer arm of from 9-40 Å.

7. The immunogenic composition of claim 1, wherein the first carrier protein and/or the second carrier protein comprises tetanus toxoid, diphtheria toxoid, CRM197, tetanus toxoid fragments (TTHc), N. meningitidis protein PorB, RSV virus proteins, Bordetella pertussis proteins, Pertussis toxoid (PT), adenylate cyclase toxin (ACT), Human Papilloma viral protein antigens, a Human Papilloma viral 69 KDa protein, Human Papilloma virus VLP forms, Hepatitis B virus core antigen, Hepatitis B virus VLP forms, derivatives of HBsAg, and/or combinations thereof.

8. The immunogenic composition of claim 1, wherein a single dose comprises less than 4 micrograms.

9. The immunogenic composition of claim 1, wherein the quantity of the first and second carrier proteins is from 0.5% to 0.8%, by weight, of the conjugates.

10. The immunogenic composition of claim 1, wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 30 KDa-100 KDa.

11. The immunogenic composition of claim 1, wherein one or more of the monovalent conjugates comprise a linker.

12. The immunogenic composition of claim 1, further comprising at least one adjuvant selected from the group consisting of aluminum salt, calcium phosphate, a liposome of monophosphoryl lipid A (MPLA), saponin QS-21, and a potent TLR7/8 agonist.

13. The immunogenic composition of claim 12, wherein the aluminum salt is selected from the group consisting of aluminum phosphate, aluminum sulfate and aluminum hydroxide.

14. The immunogenic composition of claim 1, wherein the second collection includes Streptococcus pneumoniae serotypes 6A, 6B, 6C, and 6D, Streptococcus pneumoniae serotypes 9V, 9N, 9A and 9B, Streptococcus pneumoniae serotypes 15B, 15A, and 15C, and Streptococcus pneumoniae serotypes 19A and 19F.

15. The immunogenic composition of claim 14, further comprising capsular polysaccharides of one or more serotypes of Haemophilus influenza type a and/or b; Group B Streptococcus, Moraxella catarrhalis lipo-oligosaccharides (LOS), non-typable Haemophilus influenzae (NTHi) and/or Neisseria meningitis.

16. The immunogenic composition of claim 1, wherein the second group conjugates comprise bivalent conjugates and the capsular polysaccharides of the bivalent conjugates have a molecular weight of from 100 KDa-300 KDa.

17. The immunogenic composition of claim 1, wherein administration of a single dose generates a lower immune response to the carrier protein in comparison to administration of a similar conjugate containing only monovalent conjugates of the same polysaccharides.